Clinical Trial

Lysosomal Acid Lipase Deficiency in Risk Groups

Study acronym: HELIOS
Terminated
View on ClinicalTrials.gov →
Why the trial stopped
This decision is based on a reassessment of the current need for this study, impracticality of opening study sites in outpatient clinics due to administrative and legal constraints.
Summary
A multicenter real-world observational study of the prevalence, diagnostic pathways, and clinical characteristics of lysosomal acid lipase deficiency in pediatric and adolescent risk groups in the Russian Federation (HELIOS)
Protocol Amendment History 5 changes
critical Trial terminated 2026-07-09
critical Reason stopped changed: — → This decision is based on a reassessment of the current need for this study, impracticality of opening study sites in outpatient clinics due to administrative and legal constraints. 2026-07-09
notable Enrollment reduced: 1200 -> 25 participants 2026-07-09
notable Primary completion moved earlier: 2028-06-30 -> 2026-06-04 2026-07-09
minor Completion moved earlier: 2028-06-30 -> 2026-06-04 2026-07-09
Trial Details
NCT Number NCT07455864
Lead Sponsor AstraZeneca
Conditions Lysosomal Acid Lipase Deficiency
Enrollment 25 participants
Start Date 2026-02-25
Primary Completion 2026-06-04 (estimated)
Study Completion 2026-06-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-08